Regeneron Pharmaceuticals, Inc. (REGN) - יחס שווי שוק לערך בספרים

Regeneron Pharmaceuticals maintains an impeccable reputation in medicine due to the creation of life-saving drugs. The company independently develops its scientific base and production, engaging external contractors only for the final stages of testing. The VelocImmune technological platform and patent protection provide a robust competitive advantage. The GURU.Markets portal contains the current market-to-book ratio, where the indicator stands at 2.66.

This indicator reflects the market-to-book value premium, measuring the extent to which investors overvalue assets relative to their book value. Analyzing the historical market-to-book ratio confirms that the high premium for Regeneron Pharmaceuticals (REGN) is justified by its ownership of the VelocImmune platform and blockbuster patents, which create a fundamental defensive moat for the business.